The objective is to study in a prospective, interventional, single arm, cohort study the
potential synergistic diuretic effect of empagliflozin, in addition to furosemide, in
hypervolemic patients admitted with acutely decompensated heart failure and diuretic
resistance at the McGill University Health Centre (MUHC).
The investigators hypothesize that the sodium-glucose cotransporter-2 (SGLT-2) inhibitor
empagliflozin will enhance the diuretic effect of furosemide in patients with acutely
decompensated heart failure, moderate to advanced chronic kidney disease, and underlying
diuretic resistance, as identified by the three-hour urine output post diuretic
administration on the first day of the study, compared with furosemide alone.
Phase:
Phase 4
Details
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre